



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bartley, et al.

Serial No.: 08/347,780

Group Art Unit No.: 1812

Filed: November 30, 1994

Examiner: Spector, L.

For: COMPOSITIONS AND METHODS FOR STIMULATING
MEGAKARYOCYTE GROWTH AND DIFFERENTIATION

Docket No.: A-290C

#20
M.G.J.
2/26/97

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

Under the guidelines of 37 C.F.R. 1.97, applicant(s) submit(s) a copy of (each of) the reference(s) listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner. The Examiner is directed to U.S. patent application Serial No. 08/252,628 for a copy of each of the listed references.

Publication C238 is co-authored by some of the present inventors and describes the works that led to the current invention.

Publication C239, C240, C242 and C243 relate to the receptor for thrombopoietin and its viral homolog.

Publication C241 relates to the precursor cell for megakaryocytes and erythrocytes.

Publication C244 relates to the cloning of thrombopoietin.

The claimed invention is believed to be patentable over the above-cited publications.

RECEIVED
97 JAN 29 PM 3:03
GROUP 180

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$230.00).

Please charge Deposit Account No. 01-0519 in the amount of \$230.00 (37 CFR 1.97(c)). The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,




Frank Ungemach
Attorney/Agent for Applicants
Registration No. 34,449
Phone: (805) 447-2234

Dated: 12-18-96

Please send all future correspondence to:
U.S. Patent Operations/RRC
M/S 10-1-B
AMGEN INC.
1840 Dehavilland Drive
Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231, on the date appearing below.



Debra A. Killion



Date